YOLFTbeta
Cowealth Medical China Co.Ltd.

Cowealth Medical China Co.Ltd.

603122 · SHG · Healthcare / Diagnostics & Research

11.09CNY-1.23 (-9.98%)

Price History

Full chart

Market Stats

Previous Close12.32
Open11.92
Day Range11.09 – 11.92
52-Week Range6.12 – 31.22
Volume39.89M
Market Cap5.52B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.08
Dividend Yield0.00%
Beta-0.15
50-Day Avg12.52
200-Day Avg15.00

About

Cowealth Medical China Co.,Ltd. operates as a medical company in China. It offers centralized procurement services for in-vitro diagnostic reagents and consumables; platform for decision-making and analysis, commercialization of achievements in medical science and technology; a multi-channel coaxial time audio video imaging platform; and an AI-assisted system for clinical diagnosis. The company was founded in 1997 and is based in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryDiagnostics & Research
  • CEOMs. Qiongzhi Wang
  • Employees161
  • HeadquartersGuangqi Building, Shanghai, China, 200233, China
  • Websitehttps://ch.cowealth.com

Leadership

  • Ms. Qiongzhi WangGM, CFO & Director · b. 1957
  • Mr. Guankai ZengDeputy GM & Director · b. 1977
  • Ms. Ying ZhuSecretary · b. 1976
  • Ms. Ye ChenDeputy General Manager · b. 1978
  • Mr. Fenghua WangDeputy General Manager · b. 1962
  • Mr. Shengrong YangDeputy General Manager · b. 1962
  • Heng Zheng GaoAccounting Supervisor

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue1.05B1.09B1.19B1.28B1.09B939.14M677.79M
Growth (%)-+4.02%+9.37%+7.44%-14.62%-14.05%-27.83%
Cost of Revenue816.05M864.40M940.89M1.02B866.49M755.05M577.78M
Gross Profit230.92M224.62M250.17M257.56M226.11M184.09M100.01M
Gross Margin22.06%20.63%21.00%20.13%20.69%19.60%14.76%
Operating Expense115.22M108.27M137.44M145.16M158.50M148.01M123.54M
Operating Income115.70M116.35M112.73M112.41M67.62M36.08M-23.53M
Operating Margin11.05%10.68%9.46%8.78%6.19%3.84%-3.47%
EBITDA117.50M118.39M128.86M129.79M83.14M53.16M-27.54M
EBITDA Margin11.22%10.87%10.82%10.14%7.61%5.66%-4.06%
Net Income67.14M72.55M80.23M82.72M47.19M27.57M-33.64M
Net Income Margin6.41%6.66%6.74%6.46%4.32%2.94%-4.96%
R&D---2.80M3.18M3.75M3.81M
R&D as % of Total Revenue---0.22%0.29%0.40%0.56%
Interest Expense5.64M3.37M4.55M4.24M5.88M3.32M2.32M
Interest Expense % of Total Revenue0.54%0.31%0.38%0.33%0.54%0.35%0.34%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets1.13B1.11B1.12B1.56B1.46B1.49B1.43B
Total Liabilities340.68M394.94M324.78M380.49M292.49M319.44M368.90M
Total Equity789.41M717.02M795.83M1.18B1.17B1.17B1.06B
Cash56.25M247.07M146.60M326.86M197.89M260.84M106.47M
Net Debt28.14M------

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-37.89M74.15M7.01M-30.37M11.28M132.75M17.68M
Capital Expenditure27.81M8.11M22.12M25.94M67.96M31.82M14.21M
Free Cash Flow-65.70M66.05M-15.11M-56.31M-56.68M100.93M3.47M
Dividends Paid41.08M46.20M79.65M74.54M65.25M26.95M52.66M
FCF to OCF173.39%89.07%-215.53%185.44%-502.46%76.03%19.65%
Dividend Paid to FCF-62.53%69.94%-527.08%-132.36%-115.11%26.70%1515.67%

Earnings

Report DateMar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023
EPS Estimate-----
EPS Actual0.040.050.040.070.02
Surprise-----
Timing-----

Key Statistics & Ratios

Market Cap5.52B
Enterprise Value5.31B
Trailing P/E0.00
Forward P/E0.00
Price / Sales8.50
Price / Book5.20
EPS-0.08
Book Value2.61
Revenue (TTM)648.86M
Gross Profit (TTM)95.47M
EBITDA-33.66M
Profit Margin-5.21%
Operating Margin0.40%
Return on Equity-3.13%
Return on Assets-1.65%
Shares Outstanding398.05M
Shares Float172.48M
Beta-0.15
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20251×
0.13Jul 14, 2025
20241×
0.06Jun 21, 2024
20231×
0.15Jun 21, 2023
20221×
0.18Jun 22, 2022